Jennison Associates’s Tvardi Therapeutics TVRD Stock Holding History

Jennison Associates’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-8,333	Closed	-$5.52M	–	669
2017 Q1	$5.52M	Buy	+8,333	New	+$4.45M	0.01%	506
2016 Q2	–	Sell	-18,353	Closed	-$4.11M	–	664
2016 Q1	$4.11M	Buy	18,353 +118	+0.6%	+$35.2K	﹤0.01%	498
2015 Q4	$11.1M	Buy	18,235 +56	+0.3%	+$30.7K	0.01%	477
2015 Q3	$9.35M	Buy	18,179 +11,900	+190%	+$7.97M	0.01%	513
2015 Q2	$2.75M	Buy	6,279 +63	+1%	+$24.3K	﹤0.01%	593
2015 Q1	$2.25M	Buy	6,216 +19	+0.3%	+$7.19K	﹤0.01%	596
2014 Q4	$2.22M	Sell	6,197 -6	-0.1%	-$1.93K	﹤0.01%	566
2014 Q3	$1.87M	Sell	6,203 -1,735	-22%	-$712K	﹤0.01%	589
2014 Q2	$4.86M	Sell	7,938 -1,906	-19%	-$1.03M	﹤0.01%	506
2014 Q1	$6.59M	Buy	+9,844	New	+$5.82M	0.01%	507

Other funds holding TVRD

RCP

Rho Capital Partners New York $20.4M AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jennison Associates's TVRD Position: Q2 2017 in Review

Jennison Associates sold out of Tvardi Therapeutics (TVRD) in Q2 2017, closing a stake of 8,333 shares — an estimated $5.52M sold.

Jennison Associates first reported a position in TVRD in Q1 2014 and held it in 10 quarters. The position peaked at $11.1M in Q4 2015. 127 funds tracked by Wall St. Rank hold TVRD as of Q2 2017.

Jennison Associates reported no remaining Tvardi Therapeutics position as of Q2 2017 after selling out during the quarter.
Jennison Associates sold 8,333 Tvardi Therapeutics shares in Q2 2017, an estimated $5.52M.
Jennison Associates first reported a position in Tvardi Therapeutics in Q1 2014 and held it in 10 quarters.
Jennison Associates's Tvardi Therapeutics position peaked at $11.1M in Q4 2015.
127 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2017.

Based on Jennison Associates's 13F filing for Q2 2017, filed 4 Aug 2017.